CYRXIndustrials · Integrated Freight & LogisticsThe 9 Wall Street analysts covering CryoPort, Inc. hold a median 12-month price target of $20 — +15.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 6 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores CryoPort, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Volatility (40): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CYRX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +15.3% from it.
Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 1 Oct 2026 | Guggenheim | Maintains | Buy | $16 → $19 |
| 18 Sept 2026 | BTIG | Reiterates | Buy | $25 |
| 18 Sept 2026 | BTIG | Reiterates | Buy | — |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 7 Aug 2026 | Guggenheim | Maintains | Buy | $12 → $16 |
| 7 Aug 2026 | Needham | Maintains | Buy | $15 → $19 |
| 7 Aug 2026 | Needham | Maintains | Buy | — |
| 24 July 2026 | BTIG | Maintains | Buy | — |
| 24 July 2026 | BTIG | Maintains | Buy | $17 → $25 |
| 3 June 2026 | Craig-Hallum | Maintains | Buy | $15 → $20 |
| 3 June 2026 | Craig-Hallum | Maintains | Buy | — |
| 20 May 2026 | Keybanc | Maintains | Overweight | — |
| 5 May 2026 | BTIG | Maintains | Buy | — |
| 5 May 2026 | Guggenheim | Maintains | Buy | — |
| 5 May 2026 | Needham | Maintains | Buy | — |
| 30 Mar 2026 | Craig-Hallum | Initiates | Buy | — |
| 4 Mar 2026 | Needham | Maintains | Buy | — |
| 5 Nov 2025 | Needham | Maintains | Buy | — |
| 5 Nov 2025 | UBS | Maintains | Buy | — |
| 18 Sept 2025 | BTIG | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CYRX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 7 Oct 2026, CryoPort, Inc. returned +77.0% against +17.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 51% of US stocks
Cheaper than 26% of US stocks
Cheaper than 44% of US stocks
Cheaper than 98% of US stocks
Higher than 46% of US stocks
Higher than 45% of US stocks
Higher than 58% of US stocks
Higher than 21% of US stocks
Higher than 15% of US stocks
Higher than 38% of US stocks
Higher than 36% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
CryoPort, Inc. has a market value of $901.6M and an enterprise value of $783.2M.
Revenue in the twelve months to 30 June 2026: $186.5M. The latest quarter grew 7.7% year on year.
Net income over the same four quarters: −$37.4M, a −20.1% net margin.
Diluted earnings per share, trailing twelve months: $−0.90.
Free cash flow in the twelve months to 30 June 2026: −$21.3M.
Trailing P/E: 12.7×; forward P/E: −26.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
CryoPort, Inc. employs 684 people — $273K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own CryoPort, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article compares the year-to-date performance of CryoPort, Inc. (CYRX) with that of Delcath Systems, Inc. (DCTH) relative to their medical sector. It focuses on how both companies have fared against their sector benchmark so far this year.
Why it matters — A CYRX watcher would want to know how the stock's year-to-date returns stack up against its medical-sector peers.
Seeking Alpha reports on Cryoport's strong cell and gene therapy commercialization and pipeline momentum, noting the company returned to adjusted EBITDA profitability in 2Q26 with positive operating cash flow of $8 million TTM. Management expects five new CGT commercial approvals in 2026, supported by a 15% year-over-year increase in the Phase 3 trial pipeline to 94 trials.
Why it matters — The reported return to profitability, strong operating cash flow, and expected new commercial approvals and growing Phase 3 pipeline signal expanding growth drivers for Cryoport's core cell and gene therapy business.
CryoPort (CYRX) was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects, according to Zacks Investment Research.
Why it matters — The upgrade signals improved analyst sentiment around CryoPort's earnings outlook, which CYRX watchers would take note of.
Seeking Alpha published the Q2 2026 earnings call transcript for Cryoport, Inc. (CYRX), covering the company's second-quarter financial results and management commentary. The transcript was released as part of the company's quarterly earnings reporting.
Why it matters — The transcript provides CYRX watchers with direct access to management's discussion of the company's Q2 2026 performance and outlook.
CryoPort reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations. The company reaffirmed its full-year revenue outlook of $192 million to $196 million.
Why it matters — CYRX watchers would care because reaching positive adjusted EBITDA and reaffirming the full-year outlook signal continued progress in the company's core operations.
The 9 Wall Street analysts covering CryoPort, Inc. have a median 12-month price target of $20, with estimates ranging from $15 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering CryoPort, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CryoPort, Inc. 68 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, CryoPort, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +15.3% from the last close, and Ticker Nerd's factor model ranks CryoPort, Inc. 68 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering CryoPort, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CYRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $25 over the next 12 months.
CryoPort, Inc. returned +77.0% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Cryoport Inc. is a global life sciences logistics and services company focused on temperature-controlled supply chain solutions for biologic materials.
The most recent item we track (Zacks Investment Research, 1 Oct 2026): "Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?". The article compares the year-to-date performance of CryoPort, Inc. (CYRX) with that of Delcath Systems, Inc. (DCTH) relative to their medical sector. It focuses on how both companies have fared against their sector benchmark so far this year.
Cryoport Inc. is a global life sciences logistics and services company focused on temperature-controlled supply chain solutions for biologic materials. Cryoport Inc. supports the movement, storage, handling, and monitoring of sensitive products used in cell and gene therapy, biopharmaceuticals, animal health, and reproductive medicine. Its current offerings include specialized bio-logistics, bio-storage, bio-processing, cryopreservation, and cryogenic equipment, along with related software and monitoring tools designed to help maintain product integrity throughout transit and storage. Through its Life Sciences Services and Life Sciences Products segments, Cryoport Inc. serves biotechnology and pharmaceutical companies, contract research organizations, fertility clinics, and other healthcare-focused customers worldwide. Headquartered in Brentwood, Tennessee, Cryoport Inc. plays an important role in the infrastructure that supports advanced therapies and other temperature-sensitive life sciences applications.
CEO Mr. Jerrell W. Shelton · 684 employees · United States · https://www.cryoportinc.com
